GLP-1 drugs and gastroparesis: separating real risk from TikTok panic

What did @bourbonrx actually say?

The creator, who identifies as a primary care provider, addressed whether GLP-1 medications like semaglutide and tirzepatide can cause gastroparesis, colloquially called "stomach paralysis." They referenced active lawsuits, cited a risk of "1% or less," and pushed a reasonable message: stay under provider supervision and report symptoms early. The implicit pitch was for regulated telehealth over unmonitored peptide purchases online.

The overall tone was measured. They didn't claim the medications are dangerous on balance, and they correctly noted that in at least one lawsuit case, the medication reportedly wasn't stopped despite repeated ER visits. That's a fair point about how adverse events can escalate when warning signs are ignored. Credit where it's due: this was not a fearmongering video, and it didn't recommend stopping medication without a provider's input.

Does the science back this up?

The gastroparesis association is real, but the "1% or less" figure is murkier than the creator implies. The actual evidence is a mix of case reports, pharmacovigilance data, and a few retrospective studies, not clean clinical trial numbers.

A 2023 retrospective cohort study published in JAMA (Sodhi et al., 2023) found that GLP-1 receptor agonists were associated with a significantly higher risk of gastroparesis compared to non-GLP-1 weight-loss drugs, with an adjusted incidence rate ratio of 3.67 for gastroparesis specifically. That's not a tiny signal. However, the absolute risk remains low in the general population, and the study population had diabetes, which itself is a known risk factor for gastroparesis independent of medication.

The FDA added gastroparesis as a labeled risk for semaglutide in 2023, which tells you the signal is credible enough to warrant formal acknowledgment. But saying the risk is "1% or less" without sourcing that number is imprecise. Clinical trial adverse event rates for GI slowing hovered well below 1% for confirmed gastroparesis specifically, though nausea and delayed gastric emptying are far more common and exist on a spectrum.

What did they get wrong (or right)?

The "1% or less" claim isn't necessarily wrong, but it's presented with more confidence than the data supports. Confirmed, diagnosed gastroparesis in clinical trial data is rare. But delayed gastric emptying that doesn't meet the diagnostic threshold for gastroparesis is considerably more common, and the creator conflates these a bit by using "stomach paralysis" as a catch-all.

They also mispronounced both drug names repeatedly, which is a minor credibility issue but worth noting when the platform is medical advice-adjacent content.

What they got right is more important:

• Gastroparesis risk is real but low in absolute terms.
• Escalating GI symptoms that go unaddressed are the actual danger, not the medication taken responsibly under supervision.
• GI history is a legitimate pre-treatment conversation point. Patients with pre-existing gastroparesis or diabetic autonomic neuropathy are at higher baseline risk.
• The warning against unmonitored "research grade peptides" is appropriate. Compounded or unregulated peptides carry no FDA oversight, no verified dosing, and no safety monitoring infrastructure.

The lawsuit framing was somewhat anecdotal, but the underlying lesson, that ignored warning signs become serious complications, is clinically sound.

What should you actually know?

Gastroparesis from GLP-1 medications is a documented risk, not a myth manufactured by plaintiffs' attorneys. The FDA labeled it. The pharmacovigilance data flagged it. The Sodhi et al. 2023 JAMA study showed a real signal. That said, the absolute risk for most patients is low, and GLP-1 medications carry substantial documented benefits for glycemic control and cardiovascular outcomes in appropriate populations.

The practical takeaway is what the creator said, though they undersold the specificity: if you're on a GLP-1 and you develop persistent nausea, vomiting, feeling full after minimal food intake, or significant upper abdominal discomfort, those are symptoms to report immediately, not push through. Repeated ER visits without medication adjustment, as allegedly described in the lawsuit, represents a failure of clinical management, not an inevitable drug outcome.

If you have a history of diabetic neuropathy, prior gastroparesis, or significant GI motility issues, that conversation with your provider before starting a GLP-1 is not optional. It's the baseline standard of care. Anyone prescribing semaglutide or tirzepatide without asking about GI history is cutting corners.

FormBlends bottom line

This video earns a mostly-accurate rating overall. The core message is defensible: gastroparesis risk exists, it's uncommon, and provider monitoring is the appropriate response. The specific "1% or less" figure is unsourced and probably too tidy for what is genuinely a more complicated risk picture. The framing around lawsuits and "research grade peptides" served a promotional subtext, but the clinical advice itself was not harmful. If you're on a GLP-1, keep your provider in the loop on GI symptoms. That part is simply correct.